8 min.
There are a couple of ongoing trials examining the combination of immunotherapy and targeted therapy. One of them is the KEYNOTE-022 trial. Dr. Pier Francesco Ferrucci comments on the efficacy and toxicity of the combination of pembrolizumab, dabrafenib and trametinib in comparison to dabrafenib, trametinib and placebo.